Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edmund A Rossi

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Mabs|March 16, 2013
Monoclonal antibodies targeting CD20Chien-Hsing Chang, Edmund A Rossi, David M Goldenberg
Plos One|May 21, 2014
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of LupusEdmund A Rossi, Chien-Hsing Chang, David M Goldenberg
Bioconjugate Chemistry|December 16, 2011
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structuresEdmund A Rossi, David M Goldenberg, Chien-Hsing Chang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivityChien-Hsing Chang, Edmund A Rossi, David M Goldenberg
Trends in Pharmacological Sciences|June 29, 2012
Complex and defined biostructures with the dock-and-lock methodEdmund A Rossi, David M Goldenberg, Chien-Hsing Chang
Blood|July 15, 2010
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodiesRobert M Sharkey, Edmund A Rossi, Chien-Hsing Chang, et al.
Biotechnology Progress|April 8, 2011
A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell linesDiane L Rossi, Edmund A Rossi, David M Goldenberg, et al.
Bioconjugate Chemistry|November 3, 2012
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo propertiesEdmund A Rossi, Chien-Hsing Chang, Thomas M Cardillo, et al.
Cancer Research|September 30, 2010
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cellsEdmund A Rossi, Diane L Rossi, Rhona Stein, et al.
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Mabs|March 16, 2013
Monoclonal antibodies targeting CD20Chien-Hsing Chang, Edmund A Rossi, David M Goldenberg
Plos One|May 21, 2014
Anti-CD22/CD20 Bispecific antibody with enhanced trogocytosis for treatment of LupusEdmund A Rossi, Chien-Hsing Chang, David M Goldenberg
Bioconjugate Chemistry|December 16, 2011
The dock-and-lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structuresEdmund A Rossi, David M Goldenberg, Chien-Hsing Chang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivityChien-Hsing Chang, Edmund A Rossi, David M Goldenberg
Trends in Pharmacological Sciences|June 29, 2012
Complex and defined biostructures with the dock-and-lock methodEdmund A Rossi, David M Goldenberg, Chien-Hsing Chang
Blood|July 15, 2010
Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemiasPankaj Gupta, David M Goldenberg, Edmund A Rossi, et al.
Cancer Biotherapy & Radiopharmaceuticals|March 2, 2010
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodiesRobert M Sharkey, Edmund A Rossi, Chien-Hsing Chang, et al.
Biotechnology Progress|April 8, 2011
A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell linesDiane L Rossi, Edmund A Rossi, David M Goldenberg, et al.
Bioconjugate Chemistry|November 3, 2012
Optimization of multivalent bispecific antibodies and immunocytokines with improved in vivo propertiesEdmund A Rossi, Chien-Hsing Chang, Thomas M Cardillo, et al.
Cancer Research|September 30, 2010
A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cellsEdmund A Rossi, Diane L Rossi, Rhona Stein, et al.
Pageof 7